N-(4-N'-乙酰氨基苯磺酰)-4-甲氧基苯胺 | 19837-89-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-N'-乙酰氨基苯磺酰)-4-甲氧基苯胺
• 英文名称: N-(4-(N-(4-methoxyphenyl)sulfamoyl)phenyl)acetamide
• 英文别名: n-{4-[(4-Methoxyphenyl)sulfamoyl]phenyl}acetamide；N-[4-[(4-methoxyphenyl)sulfamoyl]phenyl]acetamide
• CAS: 19837-89-9
• 化学式: C₁₅H₁₆N₂O₄S
• mdl: MFCD00026155
• 分子量: 320.369
• InChiKey: WNEYMXDBVUNSIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : N4-ACETYL-N1-(4-
METHOXYPHENYL)SULFANILAMIDE
CAS-No. : 19837-89-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Eye irritation (Category 2)
Skin sensitization (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
Precautionary statement(s)
P280 Wear protective gloves.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36 Irritating to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C15H16N2O4S
Molecular Weight : 320,37 g/mol
Component Concentration
N4-ACETYL-N1-(4-METHOXYPHENYL)SULFANILAMIDE
CAS-No. 19837-89-9 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point not applicable
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,303
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
Respiratory or skin sensitization
May cause sensitization by skin contact.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes serious eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(4-N'-乙酰氨基苯磺酰)-4-甲氧基苯胺 在 sodium hydroxide 、 水 作用下， 反应 1.0h， 生成 4-氨基-N-(4-甲氧基苯基)-苯磺酰胺
  参考文献：
  名称：

  哒嗪衍生物和相关化合物，第 28.1 部分哒嗪磺酰胺：合成和抗菌活性

  摘要：

  3-氯哒嗪 1 与 N –(未)取代的 4-氨基磺酰胺 3 反应得到 3-取代的氨基哒嗪 4 。此外，哒嗪-3-磺酰胺7是由哒嗪-3-磺酰氯6与不同的胺反应制备的。所有这些衍生物都通过分析和光谱研究进行了表征，并且还测试了它们对多种微生物的体外抗菌和抗真菌活性。

  DOI：

  10.1080/10426500802080246
• 作为产物：
  描述：

  苯胺 在 氯磺酸 、 碳酸氢钠 作用下， 以 neat (no solvent) 为溶剂， 反应 0.58h， 生成 N-(4-N'-乙酰氨基苯磺酰)-4-甲氧基苯胺
  参考文献：
  名称：

  新型香豆素磺胺类药物的设计、无溶剂合成及抗菌活性评价

  摘要：

  提出了一种简单、经济、绿色的香豆素双磺胺类化合物合成方法。从 2-氨基噻唑、苯胺和 4-甲氧基苯胺开始，分 6 步合成了 17 种新型香豆素磺胺类药物，收率高，纯度高。所有反应均在绿色条件下完成，不使用任何有害溶剂。产物的化学结构通过IR、1 H NMR和13 C NMR光谱和元素分析阐明。此外，使用两种葡萄球菌（革兰氏阳性）和大肠杆菌（革兰氏阴性）细菌菌株研究了合成磺胺类药物的抗菌特性。

  DOI：

  10.1007/s13738-021-02344-3

文献信息

• Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents
  作者：Xu Wang、Yong-Mo Ahn、Adam G. Lentscher、Julia S. Lister、Robert C. Brothers、Malea M. Kneen、Barbara Gerratana、Helena I. Boshoff、Cynthia S. Dowd

  DOI：10.1016/j.bmcl.2017.08.012

  日期：2017.9

  value of 90 µM against Mtb NadE. Our modeling results show that these urea-sulfonamides potentially bind to the intramolecular ammonia tunnel, which transports ammonia from the glutaminase domain to the active site of the enzyme. This hypothesis is supported by data showing that, even when treated with potent inhibitors, NadE catalysis is restored when treated with exogenous ammonia. Most of these compounds

  烟酰胺腺嘌呤二核苷酸（NAD +）合成酶催化NAD +生物合成的最后一步。NAD +的消耗对活跃和休眠的结核分枝杆菌（Mtb）均具有杀菌作用。通过抑制Mtb的NAD +合成酶（NadE），我们期望消除NAD +的产生，这将导致生长和非复制Mtb的细胞死亡。已经研究了NadE抑制剂对各种病原体的抑制作用，但很少针对Mtb进行过测试。在这里，我们报道了先前由Brouillette等人报道的一系列脲磺酰胺的扩展。在对接研究的指导下，末端苯环上的取代基发生了变化，以了解该位置上取代基的结构-活性关系。测试化合物作为重组Mtb NadE和Mtb全细胞的抑制剂。尽管母体化合物对Mtb NadE的抑制作用非常弱（IC 50  = 1000 µM），但我们发现优化后的效价提高了10倍。用4-硝基取代母体化合物苯环上的3,4-二氯基团可得到4f，这是该系列化合物中最有效的，其IC 50为50Mtb NadE的90
• Nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity
  作者：Shenghui Yu、Linna Zhang、Shifeng Yan、Peng Wang、Tino Sanchez、Frauke Christ、Zeger Debyser、Nouri Neamati、Guisen Zhao

  DOI：10.3109/14756366.2011.604851

  日期：2012.10.1

  polyhydroxylated aromatics based on caffeic acid phenethyl ester were designed and synthesized as HIV-1 integrase (IN) inhibitors. Most of these compounds inhibited IN catalytic activities in low micromolar range. Among these new analogues, compounds 9e and 9f were the most potent IN inhibitors with IC(50) value of 0.7 μM against strand transfer reaction. Their key structure-activity relationships were also

  设计并合成了四种基于咖啡酸苯乙酯的四十五种含氮多羟基化芳烃作为HIV-1整合酶（IN）抑制剂。这些化合物大多数在低微摩尔范围内抑制IN催化活性。在这些新的类似物中，化合物9e和9f是最有效的IN抑制剂，针对链转移反应的IC（50）值为0.7μM。还讨论了它们的关键结构-活性关系。
• Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27
  作者：Thanigaimalai Pillaiyar、Francesca Rosato、Monika Wozniak、Jeremy Blavier、Maëlle Charles、Céline Laschet、Thales Kronenberger、Christa E. Müller、Julien Hanson

  DOI：10.1016/j.ejmech.2021.113777

  日期：2021.12

  2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I, pEC50 6.34, Emax 100%). Here, we describe the synthesis and structure-activity relationships of a series of new derivatives and analogs of I. All products were evaluated for their ability to activate GPR27 in an arrestin recruitment assay. As a result, agonists were identified with a broad range of efficacies including partial and full agonists

  GPR27 与 GPR85 和 GPR173 一起属于三个受体的小亚家族，称为“大脑中表达的超保守受体”（SREB）。它被假定参与关键的生理过程，如神经元可塑性、能量代谢和胰腺 β 细胞胰岛素分泌和调节。最近，我们报道了第一个选择性 GPR27 激动剂，2,4-二氯-N- (4-( N-苯基氨磺酰基)苯基)苯甲酰胺 ( I , pEC 50 6.34, E max 100%)。在这里，我们描述了I的一系列新衍生物和类似物的合成和构效关系。. 在抑制蛋白募集测定中评估了所有产品激活 GPR27 的能力。结果，确定了具有广泛功效的激动剂，包括部分激动剂和完全激动剂，显示出比先导化合物I更高的功效。最有效的激动剂是 4-chloro-2,5-difluoro- N- (4-( N - phenylsulfamoyl)phenyl)benzamide ( 7y , pEC 50 6.85, E max
• Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors
  作者：Flávia F. Silveira、Juliana O. de Souza、Lucas V.B. Hoelz、Vinícius R. Campos、Valquíria A.P. Jabor、Anna C.C. Aguiar、M. Cristina Nonato、Magaly G. Albuquerque、Rafael V.C. Guido、Nubia Boechat、Luiz C.S. Pinheiro

  DOI：10.1016/j.ejmech.2020.112941

  日期：2021.1

  pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030

  在这项工作中，我们设计并合成了35种新的三唑并嘧啶，吡唑并嘧啶和喹啉衍生物作为恶性疟原虫抑制剂（3D7株）。三十种化合物表现出抗恶性疟原虫活性，IC 50值范围为0.030至9.1μM。[1,2,4]三唑并[1,5- a ]嘧啶衍生物比吡唑并[1,5- a ]嘧啶和喹啉类似物更有效。化合物20，21，23和24是最有效的抑制剂，具有IC 50值在0.030-0.086μM范围内，与氯喹等效。此外，这些化合物具有选择性，对人肝癌细胞系HepG2没有细胞毒活性。所有的[1,2,4]三唑并[1,5- a ]嘧啶衍生物均在低微摩尔至低纳摩尔范围（IC 50值为0.08-1.3μM）内抑制Pf DHODH活性，并且未显示出对Hs DHODH的明显抑制作用同源物（50μM时为0-30％）。分子对接研究表明[1,2,4]三唑并[1,5- a ]嘧啶衍生物与Pf DHODH的结合方式，与Pf DHODH酶
• Novel adenosine A3 receptor agonists
  申请人：Baraldi Giovanni Pier

  公开号：US20050250729A1

  公开（公告）日：2005-11-10

  The compounds of the following formula: wherein Ar, R and R 1 have the meanings given in the specification. This series of sulfonamido derivatives with a conserved uronamide group at the 5′ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido derivatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals.

  以下化合物的公式：其中Ar，R和R1具有规范中给出的含义。这一系列的磺酰胺衍生物在5'位置具有保守的糖醛酰胺基团，提供了优越的A3受体亲和力和选择性。这些新的腺苷受体激动剂是磺酰胺衍生物，其N-取代基为脂肪基（环状或线性）或芳香基团。